118 related articles for article (PubMed ID: 16602203)
1. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.
Mohr AM; Holcomb JB; Dutton RP; Duranteau J
Crit Care; 2005; 9 Suppl 5(Suppl 5):S37-42. PubMed ID: 16221318
[TBL] [Abstract][Full Text] [Related]
2. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.
Yank V; Tuohy CV; Logan AC; Bravata DM; Staudenmayer K; Eisenhut R; Sundaram V; McMahon D; Olkin I; McDonald KM; Owens DK; Stafford RS
Ann Intern Med; 2011 Apr; 154(8):529-40. PubMed ID: 21502651
[TBL] [Abstract][Full Text] [Related]
3. Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage.
Al-Shahi Salman R
Cochrane Database Syst Rev; 2009 Oct; (4):CD005951. PubMed ID: 19821350
[TBL] [Abstract][Full Text] [Related]
4. Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
Grounds RM; Bolan C
Crit Care; 2005; 9 Suppl 5(Suppl 5):S29-36. PubMed ID: 16221317
[TBL] [Abstract][Full Text] [Related]
5. Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial.
Naidech AM; Grotta J; Elm J; Janis S; Dowlatshahi D; Toyoda K; Steiner T; Mayer SA; Khanolkar P; Denlinger J; Audebert HJ; Molina C; Khatri P; Sprigg N; Vagal A; Broderick JP
Int J Stroke; 2022 Aug; 17(7):806-809. PubMed ID: 34427473
[TBL] [Abstract][Full Text] [Related]
6. Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.
Zhang J; Groff RF; Chen XH; Browne KD; Huang J; Schwartz ED; Meaney DF; Johnson VE; Stein SC; Rojkjaer R; Smith DH
Exp Neurol; 2008 Apr; 210(2):645-55. PubMed ID: 18291370
[TBL] [Abstract][Full Text] [Related]
7. Exploring Hematoma Expansion Shift With Recombinant Factor VIIa: A Pooled Analysis of 4 Randomized Controlled Trials.
Yogendrakumar V; Mayer SA; Steiner T; Broderick JP; Dowlatshahi D
Stroke; 2023 Dec; 54(12):2990-2998. PubMed ID: 37805927
[TBL] [Abstract][Full Text] [Related]
8. WITHDRAWN: Haemostatic drugs for traumatic brain injury.
Perel P; Roberts I; Shakur H; Thinkhamrop B; Phuenpathom N; Yutthakasemsunt S
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007877. PubMed ID: 25970597
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of eptacog alfa in nonhaemophiliac conditions.
Mallarkey G; Brighton T; Thomson A; Kaye K; Seale P; Gazarian M
Drugs; 2008; 68(12):1665-89. PubMed ID: 18681490
[TBL] [Abstract][Full Text] [Related]
10. Ultra-early hemostatic therapy for primary intracerebral hemorrhage: a review.
Mayer SA
Can J Neurol Sci; 2005 Dec; 32 Suppl 2():S31-7. PubMed ID: 16450806
[TBL] [Abstract][Full Text] [Related]
11. [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
Levi M; Friederich PW; van der Meer J
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2534-7. PubMed ID: 12532665
[TBL] [Abstract][Full Text] [Related]
12. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
Selin S; Tejani A
Issues Emerg Health Technol; 2006 Mar; (82):1-4. PubMed ID: 16602203
[TBL] [Abstract][Full Text] [Related]
13. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework.
Moltzan CJ; Anderson DA; Callum J; Fremes S; Hume H; Mazer CD; Poon MC; Rivard G; Rizoli S; Robinson S
Transfus Med; 2008 Apr; 18(2):112-20. PubMed ID: 18399845
[TBL] [Abstract][Full Text] [Related]
14. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
15. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
